Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma.
作者信息
Matsuki Ryota, Kawai Kirio, Suzuki Yutaka, Kogure Masaharu, Nakazato Tetsuya, Naruge Daisuke, Okano Naohiro, Seki Satowa, Ohmori Yoshihiko, Kawamura Naohiro, Kamma Hiroshi, Hisamatsu Tadakazu, Shibahara Junji, Mori Toshiyuki, Furuse Junji, Sakamoto Yoshihiro
机构信息
Department of Hepato-Biliary-Pancreatic Surgery, Kyorin University Hospital, Mitaka, Japan.
Department of Medical Oncology, Kyorin University Hospital, Mitaka, Japan.
出版信息
Liver Cancer. 2020 Jun;9(3):358-360. doi: 10.1159/000506202. Epub 2020 Mar 5.
Abstract
摘要
相似文献
1
Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma.
Liver Cancer. 2020 Jun;9(3):358-360. doi: 10.1159/000506202. Epub 2020 Mar 5.
2
Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.
Anticancer Res. 2019 Oct;39(10):5695-5701. doi: 10.21873/anticanres.13768.
3
Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report.
Onco Targets Ther. 2019 Sep 9;12:7355-7359. doi: 10.2147/OTT.S217123. eCollection 2019.
4
[Value of lenvatinib for the treatment of advanced hepatocellular carcinoma].
Zhonghua Yi Xue Za Zhi. 2020 Mar 24;100(11):833-836. doi: 10.3760/cma.j.cn112137-20190818-01832.
5
Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
Anticancer Res. 2019 Dec;39(12):6895-6901. doi: 10.21873/anticanres.13909.
6
The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.
Hepatol Int. 2019 Mar;13(2):199-204. doi: 10.1007/s12072-019-09929-4. Epub 2019 Jan 22.
7
Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.
Clin J Gastroenterol. 2019 Aug;12(4):341-346. doi: 10.1007/s12328-019-00938-2. Epub 2019 Jan 31.
8
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
J Gastroenterol. 2017 Apr;52(4):512-519. doi: 10.1007/s00535-016-1263-4. Epub 2016 Oct 4.
9
Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
Oncology. 2019;97(2):75-81. doi: 10.1159/000499715. Epub 2019 Jun 26.
10
Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma.
Case Rep Gastroenterol. 2020 Feb 5;14(1):63-69. doi: 10.1159/000505774. eCollection 2020 Jan-Apr.
引用本文的文献
1
Role of liver resection in the era of advanced systemic therapy for hepatocellular carcinoma.
Glob Health Med. 2024 Jun 30;6(3):170-173. doi: 10.35772/ghm.2024.01002.
2
A patient alive without disease 32 months after conversion surgery following lenvatinib treatment for hepatocellular carcinoma with a tumor thrombus originating in the middle hepatic vein and reaching the right atrium via the suprahepatic vena cava: a case report.
Clin J Gastroenterol. 2024 Apr;17(2):311-318. doi: 10.1007/s12328-023-01909-4. Epub 2024 Jan 26.
3
Conversion surgery after lenvatinib treatment for multiple lung metastases from hepatocellular carcinoma.
Int Cancer Conf J. 2022 Aug 17;12(1):7-13. doi: 10.1007/s13691-022-00567-6. eCollection 2023 Jan.
4
Clinical effectiveness of surgical treatment after lenvatinib administration for hepatocellular carcinoma.
Int J Clin Oncol. 2022 Nov;27(11):1725-1732. doi: 10.1007/s10147-022-02229-2. Epub 2022 Aug 12.
5
Regression of Tumor Thrombus in the Suprahepatic Vena Cava of Hepatocellular Carcinoma and Conversion Hepatectomy Induced by Lenvatinib.
Liver Cancer. 2021 Nov 11;11(3):278-280. doi: 10.1159/000520822. eCollection 2022 Jun.
6
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.
Int J Clin Oncol. 2022 Jul;27(7):1110-1119. doi: 10.1007/s10147-022-02166-0. Epub 2022 May 8.
7
Successful treatment with laparoscopic surgery and sequential multikinase inhibitor therapy for hepatocellular carcinoma: A case report.
World J Gastrointest Surg. 2022 Mar 27;14(3):260-267. doi: 10.4240/wjgs.v14.i3.260.
8
Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma.
Liver Cancer. 2021 Feb;10(1):1-9. doi: 10.1159/000514194. Epub 2021 Jan 28.
9
Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy.
Surg Case Rep. 2020 Dec 10;6(1):318. doi: 10.1186/s40792-020-01078-3.
本文引用的文献
1
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
2
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
J Hepatol. 2017 Jun;66(6):1166-1172. doi: 10.1016/j.jhep.2017.01.012. Epub 2017 Jan 26.
3
Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.
J Clin Oncol. 2012 Dec 20;30(36):4566-72. doi: 10.1200/JCO.2012.45.2854. Epub 2012 Nov 13.
4
Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.
Liver Int. 2011 May;31(5):740-3. doi: 10.1111/j.1478-3231.2010.02441.x. Epub 2011 Jan 11.
5
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19.
Zotero 插件